Please join us to learn how First Trimester Screening can benefit your patients
Speaker: Terrence Hallahan, Ph.D., Laboratory Director
Webinar Option 1: Tuesday, April 7th @ 12:00pm EST
Click here to register for Tuesday’s call
Webinar Option 2: Thursday, April 9th @ 4:00pm EST
Click here to register for Thursday’s call
The early weeks of pregnancy can be an exciting, but anxious time. Like many expectant mothers, you may want to know the facts about your baby’s risk for chromosomal abnormalities.
For years, leading ObGyns and maternal fetal medicine specialists have recognized PerkinElmer Labs/NTD as the innovator in prenatal screening for open neural tube defects and Down syndrome.
The sooner you know your risk for preeclampsia, the better. Patients and their physicians now have a first-of-its-kind blood test to screen for early onset preeclampsia during the first trimester.
PerkinElmer Labs/NTD has been a leader in the development of prenatal screening tests for over 30 years. The lab's first trimester prenatal screening test for Down syndrome, First Trimester Screen | Fβ , uses a non-invasive method to determine a patient's risk for having a baby with Down syndrome, trisomy 18, or trisomy 13 earlier in the pregnancy than alternative protocols, and with higher detection rates and lower false positive rates. It is the only high sensitivity prenatal screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in assessing individual patient risk for a fetus with Down syndrome. With the use of this screen, physicians can provide earlier assurance and earlier answers at a 91% detection rate and a 5% false positive rate (sensitivity increases to a 95% detection rate at a 2% false positive rate when patients undergo a prenatal fetal nasal bone assessment as well).
PerkinElmer Labs/NTD also offers the first biochemical screening test for early onset preeclampsia. This screen provides a detection rate as high as 91% at a 5% false positive rate for early onset preeclampsia, when combined with two additional biophysical markers: uterine artery Doppler pulsatility index (UtAD-PI) and mean arterial blood pressure (MAP).
The turnaround time for aneuploidy screening results (first and second trimester) at PerkinElmer Labs/NTD averages 1-2 business days from sample receipt.
(References 13, 25, 36)
DISCLAIMER: Pursuant to applicable federal and/or state laboratory requirements, PerkinElmer Labs/NTD has established and verified the accuracy and precision of its testing services. Tests are developed and performance characteristics determined by PerkinElmer Labs/NTD. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.